NFX
NEUTRALNuformix Receives Orphan Drug Designation for NXP002 in IPF
The pharmaceutical company has received Orphan Drug Designation for its NXP002 programme in the treatment of idiopathic pulmonary fibrosis.
Nuformix
0.1037GBX
-1.28%
Market Cap
2.07M
Volume
8.98M
15% of avg
P/E Ratio
EPS (TTM)
Beta
0.97
Day Range
0.1025p - 0.1100p
52 Week Range
0.0400p0.1037p0.3000p
0.1037p
Upcoming Events
Q4 2025
Expected update on NXP002 development and potential partnerships
High Impact Event
December 2025
Potential need for additional funding round
High Impact Event
NFX
BADNuformix Raises £210,000 Through Discounted Placing
The biotechnology company has raised £210,000 through a discounted share placing, signaling potential financial difficulties and low investor appetite.
NFX
NEUTRALNuformix to Present NXP002 Data at American Thoracic Society Congress
The pharmaceutical company will present data on its NXP002 drug candidate at an upcoming medical conference.
NFX
BADNuformix Reports Increased Losses and Cash Burn in Half-Year Results
The pre-revenue biotech firm reported widening losses and a shrinking cash balance, raising concerns about its ability to fund ongoing drug development programs without significant additional financing.
NFX
GOODNuformix Receives Positive Opinion for Orphan Drug Designation in IPF
The pharmaceutical company has received positive opinion for Orphan Drug Designation from the European Medicines Agency for its IPF treatment, a significant regulatory milestone.
NFX
BADNuformix Raises £13,200 Through Warrant Exercise, Shares Plunge
The biotechnology company has raised £13,200 through the exercise of warrants, issuing new shares at a 55% discount to the previous closing price. This large discount suggests low investor confidence and could signal financial distress.
NFX
BADNuformix Raises £13,200 Through Warrant Exercise
The biotechnology company has raised £13,200 through the exercise of broker warrants, but at a 54.55% discount to the previous closing price, suggesting low market confidence.
NFX
GOODNuformix Announces Positive NXP002 Results in Lung Tissue Models
The pharmaceutical company reports positive results from its analysis of lung tissue samples, suggesting its lead drug candidate NXP002 has potential to treat fibrotic diseases like IPF and autoimmune ILD.
NFX
NEUTRALNuformix Announces Posting of Annual Report and Notice of AGM
The pharmaceutical company has posted its annual report and notice of the upcoming annual general meeting.
NFX
NEUTRALNuformix Raises £168,750 Through Placing to Fund Pipeline Development
The pharmaceutical developer has announced a £168,750 placing to progress its pipeline and fund general corporate purposes. The raise represents a 17.6% dilution of existing shares, but is being conducted at a premium to the current share price.